Literature DB >> 10374361

Fifteen years' review of advanced childhood neuroblastoma from a single institution in Hong Kong.

C K Leung1.   

Abstract

OBJECTIVE: To assess the progress in the treatment of advanced childhood neuroblastoma.
METHODS: From 1981 to 1996, there were 32 children with neuroblastoma (NB) diagnosed, staged and treated in our institution. There were 4 patients with stage II NB (12%), 5 stage III (16%), 21 stage IV (66%) and 2 stage IV s (6%). The NBs were excised if CT scan indicated that the tumors were operable. For advanced NB, stages III and IV, multiple drug chemotherapy was started first and operability was assessed with serial CT scan examinations. Once the X-ray imaging indicated the tumors were operable, surgical interventions were done. The medical records of the advanced NB were reviewed.
RESULTS: In the initial period of the study, 9 patients were treated using the VAC protocol [vincristine (vcr), adriamycin (adria) and cyclophosphamide (cyc)]. No patient was convertible to operable and all died with a mean survival of 10 months. OPEC [vcr, cyc, VM26, cisplatin (cis)], Rapid COJEC (carboplatin, VP16, vcr, cis and cyc) and more recently N6 protocol (cyc, adria, vcr, VP16, cis) was used for 17 patients. 80% of them were converted to operable. In 4 patients, surgical specimens showed only necrotic tissue without viable tumor tissue and 6 (35%) tumors were converted to ganglioneuroma or ganglioneuroblastoma. Although 2 (12%) patients died of fungal septicemia and 1 (6%) developed Fanconi's syndrome after chemotherapy, the mean survival period increased to 27 months. In the 10 survivors (60%), 4 had megatherapy with melphalan followed by autologous peripheral blood stem cell (PBSC) transplantation and 2 were waiting for transplantation.
CONCLUSIONS: There is a high percentage of advanced NB on presentation in Hong Kong. With more potent multiple drug chemotherapy for advanced stage NB there are (1) improvement in the survival of these patients, (2) opportunities for more operations for tumor excision and (3) opportunities for autologous PBSC transplantation for better tumor eradication.

Entities:  

Mesh:

Year:  1998        PMID: 10374361

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  5 in total

1.  Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.

Authors:  Chi-Yi Jiang; Xiao Xu; Bing-Lin Jian; Xue Zhang; Zhi-Xia Yue; Wei Guo; Xiao-Li Ma
Journal:  Ital J Pediatr       Date:  2021-06-09       Impact factor: 2.638

2.  Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.

Authors:  Yan Su; Lijun Wang; Xisi Wang; Zhixia Yue; Tianyu Xing; Wen Zhao; Qian Zhao; Chao Duan; Cheng Huang; Yi Han; Lihua Qiu; Xianfeng Cheng; Yi Liu; Xiaoli Ma
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

3.  Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma.

Authors:  Yan Su; Lijun Wang; Chiyi Jiang; Zhixia Yue; Hongjun Fan; Huimin Hong; Chao Duan; Mei Jin; Dawei Zhang; Lihua Qiu; Xianfeng Cheng; Zhong Xu; Xiaoli Ma
Journal:  BMC Cancer       Date:  2020-02-06       Impact factor: 4.430

4.  Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma.

Authors:  Xisi Wang; Lijun Wang; Yan Su; Zhixia Yue; Tianyu Xing; Wen Zhao; Qian Zhao; Chao Duan; Cheng Huang; Dawei Zhang; Mei Jin; Xianfeng Cheng; Shenglan Chen; Yi Liu; Xiaoli Ma
Journal:  Cancer Med       Date:  2018-06-14       Impact factor: 4.452

5.  Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.

Authors:  Yan Su; Lijun Wang; Qian Zhao; Zhixia Yue; Wen Zhao; Xisi Wang; Chao Duan; Mei Jin; Dawei Zhang; Shenglan Chen; Jianfeng Yin; Lihua Qiu; Xianfeng Cheng; Zhong Xu; Xiaoli Ma
Journal:  Mol Oncol       Date:  2020-09-18       Impact factor: 7.449

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.